Healthcare / BiotechnologyStockholm
$10.60
+0.60 (+6.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-390.3M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$218M
P/E
132.5x
↑EV/EBITDA
N/A
•ROE
22.7%
↑Gross Margin
58.8%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+38.2%
FCF CAGR
—
FCF margin
-256.1%
FCF / Net income
-3.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $152.4M · net income $127.2M · FCF $-390.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $152.4M | $152.4M | $148.1M | $238.8M | $57.7M |
| Net Income | $127.2M | $127.2M | $-266.2M | $-388.2M | $-172.5M |
| EBITDA | $-10.8M | $-10.8M | $-63.2M | $-269.8M | $-165.9M |
| EPS | 0.08 | 0.08 | -27.50 | -82.50 | -0.77 |
| Gross Margin | 58.8% | 58.8% | 87.7% | 14.8% | 99.9% |
| Operating Margin | -44.7% | -44.7% | -80.6% | -129.8% | -300.8% |
| Net Margin | 83.5% | 83.5% | -179.8% | -162.6% | -299.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.92 | 1.35 | 0.09 |
| Current Ratio | 3.03 | 3.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-390.3M | $-390.3M | $-186.0M | $-423.4M | $-254.0M |
| Returns | |||||
| ROE | 22.7% | 22.7% | -127.7% | -226.6% | -40.6% |
| Valuation | |||||
| P/E | 132.50 | 132.50 | — | — | — |
| P/B | 0.31 | 0.31 | 1.04 | 3.62 | 578.48 |
| Growth & Yield | |||||
| Revenue Growth | 2.9% | 2.9% | -38.0% | 313.9% | — |
| EPS Growth | 100.3% | 100.3% | 66.7% | -10681.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
127.4%
EPS terminal req.
$0.94
Spread vs growth
-27.1%
5Y implied EPS CAGR
70.1%
EPS terminal req.
$1.14
Spread vs growth
30.2%
10Y implied EPS CAGR
36.8%
EPS terminal req.
$1.83
Spread vs growth
63.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-27.50 → 0.08
Residual
-60.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.